Tags

Type your tag names separated by a space and hit enter

HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma.
Otolaryngol Head Neck Surg 2009; 140(2):228-34OH

Abstract

OBJECTIVE

To determine if patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) treated with chemoradiation have improved outcomes.

STUDY DESIGN

A retrospective search was used to identify patients with OPSCC treated with concurrent chemoradiation. Pretreatment biopsy specimens were tested for HPV-16 infection and p16 expression.

METHODS

Forty-four patients with OPSCC treated with concurrent chemotherapy and intensity-modulated radiation therapy were identified. Eligibility criteria included a minimum two years of follow-up, or biopsy-proven recurrence. In situ hybridization was applied to archival tumor specimens, with HPV-16-positive status defined as positive staining of tumor cell nuclei. p16 expression was assessed by immunohistochemistry.

RESULTS

Twenty-seven tumors (61%) were positive for HPV-16 and 29 tumors (66%) expressed p16. HPV-16 infection was highly correlated with p16 expression (P < 10(-7)). Three-year disease-free and overall survival for all patients was 66 percent and 79 percent respectively. Patients with tumors infected with HPV-16 had improved overall (OS) and disease-free survival (DFS) after chemoradiation (OS: hazard ratio [HR] = 0.21, P = 0.01; DFS: HR = 0.30, P = 0.02).

CONCLUSION

Patients with OPSCC tumors that are infected with HPV-16 have improved survival after treatment with concurrent chemoradiation.

Authors+Show Affiliations

Department of Otology and Laryngology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19201294

Citation

Nichols, Anthony C., et al. "HPV-16 Infection Predicts Treatment Outcome in Oropharyngeal Squamous Cell Carcinoma." Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery, vol. 140, no. 2, 2009, pp. 228-34.
Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2009;140(2):228-34.
Nichols, A. C., Faquin, W. C., Westra, W. H., Mroz, E. A., Begum, S., Clark, J. R., & Rocco, J. W. (2009). HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery, 140(2), pp. 228-34. doi:10.1016/j.otohns.2008.11.025.
Nichols AC, et al. HPV-16 Infection Predicts Treatment Outcome in Oropharyngeal Squamous Cell Carcinoma. Otolaryngol Head Neck Surg. 2009;140(2):228-34. PubMed PMID: 19201294.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. AU - Nichols,Anthony C, AU - Faquin,William C, AU - Westra,William H, AU - Mroz,Edmund A, AU - Begum,Shanaz, AU - Clark,John R, AU - Rocco,James W, PY - 2008/09/05/received PY - 2008/10/31/revised PY - 2008/11/13/accepted PY - 2009/2/10/entrez PY - 2009/2/10/pubmed PY - 2009/4/1/medline SP - 228 EP - 34 JF - Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery JO - Otolaryngol Head Neck Surg VL - 140 IS - 2 N2 - OBJECTIVE: To determine if patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) treated with chemoradiation have improved outcomes. STUDY DESIGN: A retrospective search was used to identify patients with OPSCC treated with concurrent chemoradiation. Pretreatment biopsy specimens were tested for HPV-16 infection and p16 expression. METHODS: Forty-four patients with OPSCC treated with concurrent chemotherapy and intensity-modulated radiation therapy were identified. Eligibility criteria included a minimum two years of follow-up, or biopsy-proven recurrence. In situ hybridization was applied to archival tumor specimens, with HPV-16-positive status defined as positive staining of tumor cell nuclei. p16 expression was assessed by immunohistochemistry. RESULTS: Twenty-seven tumors (61%) were positive for HPV-16 and 29 tumors (66%) expressed p16. HPV-16 infection was highly correlated with p16 expression (P < 10(-7)). Three-year disease-free and overall survival for all patients was 66 percent and 79 percent respectively. Patients with tumors infected with HPV-16 had improved overall (OS) and disease-free survival (DFS) after chemoradiation (OS: hazard ratio [HR] = 0.21, P = 0.01; DFS: HR = 0.30, P = 0.02). CONCLUSION: Patients with OPSCC tumors that are infected with HPV-16 have improved survival after treatment with concurrent chemoradiation. SN - 0194-5998 UR - https://www.unboundmedicine.com/medline/citation/19201294/HPV_16_infection_predicts_treatment_outcome_in_oropharyngeal_squamous_cell_carcinoma_ L2 - http://journals.sagepub.com/doi/full/10.1016/j.otohns.2008.11.025?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -